Bayer Kogenate FS Free Trial Launches With Bio-Set Needle Free System
This article was originally published in The Pink Sheet Daily
Executive Summary
Hemophilia A treatment promotion incorporates risk information after an earlier promotion drew FDA criticism.
You may also be interested in...
Bayer Kogenate FS Long-Acting Formula Expected To Drive Future Biologic Sales
The company plans to initiate Phase III studies this year for the first long-acting recombinant Factor VIII.
Bayer Kogenate FS Free Trial Program Fails To Include Labeling, FDA Says
The CBER ad division letter cites the promotional materials for lack of risk information and failure to provide adequate direction for use.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.